Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

UNKNOWN

Tolerability and Efficacy of RJX in Patients With COVID-19

Lead Sponsor:

Reven Pharmaceuticals, Inc.

Conditions:

COVID-19

Acute Respiratory Distress Syndrome

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

This study is designed as a 2-part, 2-cohort, double-blind, randomized, placebo controlled, multicenter Phase 1/2 study to evaluate the safety, tolerability and efficacy of RJX in patients with COVID-...

Detailed Description

For each cohort, there will be an open label Safety Lead-in (Part 1) and a placebo controlled, randomized, double-blind portion (Part 2). In Part 1, RJX will be administered daily for 7 days. In the a...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Cohort 1 (Part 1 and Part 2):
  • Hospitalized COVID-19 patients ≥18 years without hypoxemia who are either not receiving any oxygen therapy OR are receiving supplemental oxygen via mask or nasal prongs (namely, clinical status score 4 or 5 on an 8-point ordinal scale)
  • Hospitalized COVID-19 patients age ≥65 years AND type 2 diabetes or hypertension, OR
  • Hospitalized COVID-19 patients ≥18 years AND abnormal blood tests with CRP \>50 mg/L PLUS at least 1 of the following biomarkers:
  • D-dimer \>1,000 ng/mL
  • Ferritin \>500 µg/L
  • High sensitivity cardiac troponin \>2 × ULN
  • LDH \>245 U/L
  • Cohort 2 (Part 1 and Part 2):
  • Hospitalized COVID-19 patients with hypoxemia who are either receiving NIPPV OR high-flow oxygen (namely, clinical status score 3 on an 8-point ordinal scale).
  • Bilateral opacities on a chest x-ray OR chest CT scan. Cohort 1 and Cohort 2 (Parts 1 and 2)
  • Male and non-pregnant, non-lactating female patients with SARS-CoV-2 infection that is documented by a Food and Drug Administration (FDA)-authorized diagnostic reverse transcription polymerase chain reaction test at/or within 4 days of Screening
  • ≥18 years of age
  • Body weight ≥40 kg at Screening
  • History of COVID-19 within the last 2 weeks prior to study enrollment
  • The patient OR a legally authorized representative has provided written informed consent
  • Females of childbearing potential must have a negative beta human chorionic gonadotropin pregnancy test at Screening
  • Females of childbearing potential must agree to be abstinent or else use a medically acceptable form of contraception from the Screening period through Day 28. Medically acceptable forms of contraception including implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence or vasectomy, and double-barrier method \[condom and occlusive cap (diaphragm or cervical/vault caps)\] with spermicidal foam/gel/film/suppository
  • Exclusion Criteria Cohort 1
  • Receiving high-flow oxygen OR NIPPV. Cohort 1 and Cohort 2
  • ARDS by Berlin definition (Appendix 16.2)
  • On extracorporeal membrane oxygenation
  • Uncontrolled hypertension (systolic blood pressure \[BP\] \>150 mmHg and/or diastolic BP \>100 mmHg), unstable angina, congestive heart failure of New York Heart Association Classification Class III or IV (i.e., Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g., walking short distances \[20 100 m\], comfortable only at rest; Class IV: severe limitations, experiences symptoms even while at rest, mostly bedbound patients), serious cardiac arrhythmia requiring treatment (exceptions: atrial fibrillation, paroxysmal supraventricular tachycardia), history of myocardial infarction within 12 months prior to enrollment
  • Subjects with a history of congenital long QT syndrome or of Torsades de pointes; subjects with bradycardia (\<60 bpm), heart block (excluding 1st degree block, being PR interval prolongation only); subjects with any of the following findings on electrocardiogram (ECG): QTc interval \>470 msec in women OR \>450 msec in men; subjects requiring any drugs known to prolong the QTc interval, including antiarrhythmic medications
  • Shock or hypotension requiring vasoactive peptides, such as dopamine, norepinephrine, epinephrine, or dobutamine
  • Renal function impairment with creatinine ≥2 mg/dL
  • Liver function impairment with total bilirubin ≥2 mg/dL
  • Platelet count \<50,000/µL
  • Multi-organ failure
  • History of an allergic reaction or hypersensitivity to the study drug or any component of the study drug formulation
  • Use of systemic corticosteroids, nonsteroidal anti-inflammatory drugs, antibiotics, and antiviral drugs that are not part of the standard of care
  • Presence of any uncontrolled concomitant illness (e.g., bacterial sepsis or invasive fungal infection), or other serious illness and medical conditions, or other medical history, including laboratory results, which, in the Investigator's opinion, would be likely to interfere with their participation in the study
  • Pregnancy or breast-feeding (for women)

Exclusion

    Key Trial Info

    Start Date :

    March 25 2021

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    February 1 2023

    Estimated Enrollment :

    237 Patients enrolled

    Trial Details

    Trial ID

    NCT04708340

    Start Date

    March 25 2021

    End Date

    February 1 2023

    Last Update

    March 15 2022

    Active Locations (3)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (3 locations)

    1

    Memorial Hermann Memorial City Medical Center

    Houston, Texas, United States, 77024

    2

    Memorial Hermann Southeast Hospital

    Houston, Texas, United States, 77089

    3

    Christus Santa Rosa Hospital

    New Braunfels, Texas, United States, 78130